Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc .
(Nasdaq: RGLS ), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30 , 2024. "We have remained focused on rapidly progressing RGLS8429 for the potential treatment of ADPKD and were pleased to announce the completion of enrollment in our fourth and final cohort of the Phase 1b MAD study last month. Our team continues to be energized not only by the positive results we've seen so far in the clinic but also by the recent opportunities we've had to interact with the broader nephrology community and present on RGLS8429 at recent meetings," said Jay Hagan, CEO of Regulus.
"We are in a strong position as we move towards the end of the year and into 2025. We expect to share preliminary topline data from a substantial number of patients from th.